A detailed history of Royal Bank Of Canada transactions in Myriad Genetics Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 16,357 shares of MYGN stock, worth $359,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,357
Previous 9,038 80.98%
Holding current value
$359,199
Previous $192,000 108.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$17.98 - $25.47 $131,595 - $186,414
7,319 Added 80.98%
16,357 $400,000
Q1 2024

May 15, 2024

SELL
$17.59 - $23.59 $117,518 - $157,604
-6,681 Reduced 42.5%
9,038 $192,000
Q4 2023

Feb 14, 2024

BUY
$13.91 - $21.32 $103,671 - $158,897
7,453 Added 90.16%
15,719 $300,000
Q3 2023

Nov 14, 2023

BUY
$15.99 - $23.22 $111,882 - $162,470
6,997 Added 551.38%
8,266 $132,000
Q2 2023

Aug 14, 2023

SELL
$17.56 - $23.76 $134,474 - $181,954
-7,658 Reduced 85.78%
1,269 $29,000
Q1 2023

May 15, 2023

SELL
$15.26 - $23.75 $150,082 - $233,581
-9,835 Reduced 52.42%
8,927 $207,000
Q4 2022

Feb 14, 2023

BUY
$14.51 - $20.99 $238,297 - $344,718
16,423 Added 702.14%
18,762 $272,000
Q3 2022

Nov 14, 2022

BUY
$18.21 - $27.88 $9,578 - $14,664
526 Added 29.01%
2,339 $44,000
Q2 2022

Aug 15, 2022

SELL
$16.45 - $25.88 $66,392 - $104,451
-4,036 Reduced 69.0%
1,813 $33,000
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $206,795 - $255,507
-9,122 Reduced 60.93%
5,849 $148,000
Q4 2021

Feb 14, 2022

BUY
$24.13 - $32.63 $98,957 - $133,815
4,101 Added 37.73%
14,971 $412,000
Q3 2021

Nov 15, 2021

BUY
$29.97 - $36.66 $116,253 - $142,204
3,879 Added 55.49%
10,870 $352,000
Q2 2021

Aug 16, 2021

BUY
$25.39 - $32.61 $177,501 - $227,976
6,991 New
6,991 $213,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.77B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.